Patents Assigned to Wellstat Biologics Corporation
-
Patent number: 7595042Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: May 5, 2005Date of Patent: September 29, 2009Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Publication number: 20090180994Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: ApplicationFiled: March 26, 2009Publication date: July 16, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Publication number: 20090180993Abstract: Two or more desensitization doses of a therapeutic virus are administered, followed by one or more escalated doses of the virus. In addition, the rate at which a therapeutic virus is administered can be controlled.Type: ApplicationFiled: March 24, 2009Publication date: July 16, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventor: Robert M. Lorence
-
Publication number: 20090170129Abstract: Endothelial cells are detected in a blood sample by enriching the endothelial cells from the blood sample followed by performing on the enriched endothelial cells an immunoassay capable of detecting antigens expressed by the endothelial cells. The immunoassay is capable of detecting antigen expressed from 300 endothelial cells per milliliter of blood. The method can be used for assaying mature circulating endothelial cells or circulating endothelial progenitor cells.Type: ApplicationFiled: April 18, 2007Publication date: July 2, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventor: Robert M. Lorence
-
Publication number: 20090098138Abstract: The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.Type: ApplicationFiled: April 18, 2007Publication date: April 16, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventor: Robert M. Lorence
-
Publication number: 20090081161Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: ApplicationFiled: November 18, 2008Publication date: March 26, 2009Applicant: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. Von Borstel
-
Patent number: 7470426Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: April 17, 2000Date of Patent: December 30, 2008Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Publication number: 20080261243Abstract: The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).Type: ApplicationFiled: October 6, 2005Publication date: October 23, 2008Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Ming Lu
-
Publication number: 20080193419Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: ApplicationFiled: July 12, 2006Publication date: August 14, 2008Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Michael S. Roberts
-
Publication number: 20080166784Abstract: Envelope viruses (e.g. Newcastle disease virus (NDV)) are formulated for storage at moderately cold temperatures (e.g. ?20 C). The formulation is an aqueous solution containing the enveloped virus at a concentration of from 106 PFU/mL to 1012 PFU/mL; and a non-reducing saccharide (e.g. sucrose). When the non-reducing saccharide is a disaccharide it is present in the solution at a concentration of from 5% (w/v) to 50% (w/v), and when it is a monosaccharide it is present in the solution at a concentration of from 2.5% (w/v) to 25% (w/v). The solution has an osmotic pressure of about 250 mOs or higher, and has a pH of from 5 to 10.Type: ApplicationFiled: November 4, 2005Publication date: July 10, 2008Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Tzer-Fen Chen, Jouhn-Wern Jang, Jeffrey A. Miller
-
Publication number: 20070258991Abstract: Lowering the level of antibody or complement in the blood of a subject by plasmapheresis or exchange transfusion prior to administering an immunogenic therapeutic agent containing a foreign epitope reduces the immune response of the subject to the therapeutic agent.Type: ApplicationFiled: February 22, 2007Publication date: November 8, 2007Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Pete Buasen, Sylvain Cardin, Robert Lorence
-
Publication number: 20070207149Abstract: Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.Type: ApplicationFiled: April 26, 2005Publication date: September 6, 2007Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert Lorence, Michael Roberts
-
Publication number: 20070166287Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: ApplicationFiled: March 13, 2007Publication date: July 19, 2007Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: John Bell, Nahum Sonenberg, David Stojdl, Earl Brown, Harold Atkins, Ricardo Marius, Brian Lichty, Shane Knowles
-
Publication number: 20070141033Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: ApplicationFiled: February 6, 2007Publication date: June 21, 2007Applicants: WELLSTAT BIOLOGICS CORPORATION, UNIVERSITY OF OTTAWAInventors: Harold Atkins, John Bell, Conrad Heilman, Brian Lichty, Robert Lorence, Michael Roberts, David Stojdl
-
Patent number: 7192580Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: GrantFiled: November 19, 2003Date of Patent: March 20, 2007Assignees: Wellstat Biologics Corporation, University of OttawaInventors: Harold L. Atkins, John C. Bell, Conrad J. Heilman, Jr., Brian D. Lichty, Robert M. Lorence, Michael S. Roberts, David F. Stojdl
-
Patent number: 7122182Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: May 9, 2002Date of Patent: October 17, 2006Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Publication number: 20060216310Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal. The invention further provides genetically engineered Paramyxoviruses, and kits containing the viral compositions disclosed by the invention.Type: ApplicationFiled: May 26, 2006Publication date: September 28, 2006Applicant: Wellstat Biologics CorporationInventors: Robert Lorence, Kirk Reichard
-
Patent number: 7056689Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal. The invention further provides genetically engineered Paramyxoviruses, and kits containing the viral compositions disclosed by the invention.Type: GrantFiled: June 16, 1994Date of Patent: June 6, 2006Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Kirk W. Reichard
-
Publication number: 20050220818Abstract: Two or more desensitization doses of a therapeutic virus are administered, followed by one or more escalated doses of the virus. In addition, the rate at which a therapeutic virus is administered can be controlled.Type: ApplicationFiled: May 22, 2003Publication date: October 6, 2005Applicant: Wellstat Biologics CorporationInventor: Robert Lorence
-
Publication number: 20050169889Abstract: Lowering the level of antibody or complement in the blood of a subject by plasmapheresis or exchange transfusion prior to administering an immunogenic therapeutic agent containing a foreign epitope reduces the immune response of the subject to the therapeutic agent.Type: ApplicationFiled: April 22, 2003Publication date: August 4, 2005Applicant: Wellstat Biologics CorporationInventors: Pete Buasen, Sylvain Cardin, Robert Lorence